FDA warns of potential drug interaction between remdesivir, hydroxychloroquine
The Food and Drug Administration yesterday said chloroquine phosphate and hydroxychloroquine sulfate could reduce remdesivir's antiviral activity.
As a result, FDA, citing a non-clinical lab study, does not recommend co-administration of the drugs. The agency yesterday revoked emergency use authorizations for chloroquine and hydroxychloroquine for COVID-19 treatment.
Related News Articles
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…